Medicaid coverage; biomarker testing coverage; discretionary; effective date.

Summary

The bill requires the state Medicaid program to pay for biomarker tests that are supported by FDA approval, clinical guidelines, or other recognized evidence. It sets timelines for prior‑authorization decisions and ensures providers and members can easily request coverage exceptions. The change aims to improve diagnosis and treatment for Medicaid patients.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share